

## **Hepatitis C virus infection and tobacco smoking - joint health effects and implications for treatment of both: A systematic review**

**Belaynew W Taye**<sup>1,2,3,4</sup>

<sup>1</sup>Faculty of Medicine, The University of Queensland; Brisbane, Australia

<sup>2</sup>Mater Research Institute-University of Queensland, Brisbane, Australia

<sup>3</sup>Population Health, QIMR Berghofer Medical Research Institute, Brisbane, Australia

<sup>4</sup>Department of Epidemiology, Bahir Dar University, Bahir Dar, Ethiopia

## Summary

**Background:** Tobacco smoking and hepatitis C virus (HCV) infection cause many diseases independently. The interaction of these conditions on health effects has not been widely studied. There is a paucity of information on addressing tobacco smoking in HCV treatment settings. This review examines the relationship between tobacco smoking and HCV infection and health outcomes and discusses opportunities for treating both conditions.

**Methods:** A systematic review was conducted following the PRISMA 2009 guidelines (*Registration No.: CRD42019127771*). We searched PubMed, EMBASE, Web of Science, and CINAHL on the health effects of tobacco smoking and HCV infection using keywords and MeSH terms for hepatitis C, tobacco smoking, hepatocellular carcinoma (HCC), chronic obstructive pulmonary disease (COPD), diabetes mellitus (DM), cardiovascular diseases (CVD), and chronic kidney disease (CKD). We used the Newcastle-Ottawa Scale, a measurement tool to assess systematic reviews (AMSTAR-2), and international narrative systematic assessment (INSA) tools to assess the methodological quality of the included studies.

**Findings:** Tobacco smoking and HCV infection share similar underlying risk factors and hence it is unsurprising that tobacco smoking prevalence is higher in people living with HCV (PLHCV) than in the general population. Tobacco smoking and HCV infection have additive or multiplicative interaction to cause HCC, COPD, DM, CVD, and CKD. Anti-HCV direct-acting antiviral (DAA) treatment is highly efficacious and widely accessible in many countries, but untreated tobacco smoking addiction may undermine the achievement of optimal health outcomes possible from HCV treatment.

**Interpretation:** The scale-up of DAA treatment programs globally is an opportunity to address the high prevalence of tobacco smoking in PLHCV by concurrently offering tobacco smoking cessation treatment. Simultaneous initiation of smoking cessation therapy at HCV treatment centres is likely to be cost-effective at maximizing the health gains afforded by DAA treatment. Studies are needed to evaluate the effect of tobacco smoking cessation on the sustained virologic response in DAA treated patients.

**Keywords:** *smoking cessation; interaction; health effects; anti-HCV therapy; integration*

## Introduction

Hepatitis C virus (HCV) is a blood-borne infection belonging to the *Flaviviridae* family of RNA viruses with eight genotypes and over 60 subtypes.<sup>1-3</sup> Genotype 1 (G1) is the

commonest (causing 46% of HCV infections) followed by G3 (22%), G2 (13%), and G4 (13%).<sup>3,4</sup> Genotypes 5 and 6 are responsible for the remaining <5% of HCV infections.<sup>4</sup> Global HCV prevalence is estimated at 2.5% (177.5 million cases), with higher rates in European and Eastern Mediterranean regions.<sup>4-6</sup>

The risk factors for HCV infection vary widely from region to region depending on socioeconomic status, behavioural, and healthcare quality dimensions. In the Middle East and Africa, healthcare-associated exposures including blood transfusion, hemodialysis, unsafe medical injections, and surgical and dental procedures are the commonest sources of infection (59.5%) followed by injecting drug use (IDU) (20.9%), community-based exposures (15.8%), and sexual contact (3.7%).<sup>7,8</sup> IDU is the commonest risk factor for HCV infection in high-income countries (HICs) such as Australia (80%) and the US (32%).<sup>9</sup> Other risk factors for HCV infection include unsterile tattooing and body piercing, occupational exposure to infected blood, needle-stick injuries, and mother-to-child transmission.<sup>10,11</sup>

Tobacco smoking prevalence is estimated to be 21% globally and tobacco kills more than 7 million people each year.<sup>12</sup> In low-and-middle-income countries (LMICs), such as those in Latin America (21%), Central, Southern, and Western Asia (23%), and Eastern and South-eastern Asia (23.5%), more than one-in-five adults smoke tobacco.<sup>13</sup> In most HICs, tobacco smoking prevalence has dropped to well below 20%. For example, current tobacco smoking prevalence among adults was 15.6% in 2016 in Australia<sup>14</sup>, 15.5% in 2016 in the US<sup>15</sup>, and 15.1% in 2017 in the UK.<sup>16</sup> Despite substantial declines in smoking in the general population, tobacco smoking prevalence remains very high among many sub-populations including people with mental illness<sup>17</sup>, substance use disorders<sup>18</sup>, and HIV.<sup>19</sup>

Although there is a paucity of evidence regarding the prevalence of tobacco smoking in PLHCV, some studies, mostly based on clinical samples, show tobacco smoking is much higher in PLHCV than among the general population. Studies showed prevalence from more than half (52.9%)<sup>20</sup> to three-fourths (76.2%)<sup>21</sup> of PLHCV smoked tobacco.

A number of factors have been associated with tobacco smoking among PLHCV including older age, low education, low income, current use of cannabis, cocaine, heroin, harmful use of alcohol, low self-efficacy, poor social support, perceived benefit of smoking cessation, loneliness, depression and anxiety, pain, and presence of life stressors.<sup>22,23</sup>

Tobacco smoking contributes to premature death and morbidity, mainly from coronary heart disease and stroke, cancers of the lung, upper airways, liver, and stomach, miscarriage and

underdevelopment of the foetus.<sup>24</sup> Tobacco smoking is also a risk factor for chronic kidney disease (CKD), cancer of the colon and pancreas, diabetes mellitus (DM), osteoporosis, cataract and macular degenerations, and dementia.<sup>25</sup> HCV infection is also a risk factor for many diseases, including hepatocellular carcinoma (HCC), chronic obstructive pulmonary disease (COPD), cardiovascular diseases (CVD), DM, and CKD<sup>26-29</sup>. Despite this, the combined health effects of tobacco smoking and HCV infection have not been well studied at a larger scale as are the treatment opportunities for tobacco addiction in the presence of HCV infection. Co-occurrence of these two risk factors has implications for the treatment of HCV if health outcomes are to be optimized.

DAAs for treatment of HCV demonstrate a high rate of sustained virologic response (SVR) and favourable safety profile compared to previous treatments, such as interferon.<sup>30</sup> Hence, DAAs are expected to significantly reduce the prevalence of HCV in the coming decades potentially leading to its elimination.<sup>31-33</sup> While DAA treatment has high efficacy and results in a cure for >95% of those treated, PLHCV often have multiple health issues, including substance use disorders.<sup>22</sup>

This review aimed to describe the interaction between tobacco smoking and chronic HCV infection and the development of chronic health conditions. We reviewed the risk factors for tobacco smoking among PLHCV, potential joint health implications and discussed the opportunities for the treatment of both HCV infection and tobacco smoking addiction.

## **Methods**

### **Search strategy and selection criteria**

This systematic review (*Registration No.: CRD42019127771*) followed the PRISMA 2009 guidelines. We searched PubMed, EMBASE, Web of Science, and CINAHL (until July 31, 2018) for HCV infection, tobacco smoking, and key health effects including HCC, COPD, CVD, DM, and CKD by combining the keywords and MeSH terms for ‘cigarette smoking’, ‘hepatitis C virus’, ‘hepatocellular carcinoma’, ‘chronic obstructive pulmonary disease’, ‘cardiovascular diseases’, ‘diabetes mellitus’, and ‘kidney diseases’.

We included studies that assessed both tobacco smoking and HCV infection and their joint health effects (HCC, COPD, CVD, DM or CKD) in adults. Studies published in a non-English language, conducted in children, and where data on joint health effects of HCV infection and tobacco smoking could not be extracted were excluded.

Initially, all identified records were exported from each database into an EndNote library and duplicate records were removed. The lead author screened the remaining records for relevance to the review by reading the title and abstracts. Then, further screening for eligibility using the above inclusion criteria was made by reading the full text of the articles.

### **Risk of bias and quality assessment**

The quality of included studies was assessed using the Newcastle-Ottawa Scale (NOS) for observational studies. The rating scale for case-control and cohort designs was used directly<sup>34</sup> and the modified NOS for cross-sectional studies, as suggested and used by Modesti and colleagues, was used to assess the quality of cross-sectional studies.<sup>35</sup> We used a measurement tool to assess systematic reviews (AMSTAR-2) tool for assessing the methodological quality of the systematic reviews included.<sup>36</sup> In this scale, scores of 0–4 indicate low quality, 5–8 indicate moderate quality, and 9–11 indicate high quality.<sup>36</sup> We assessed the methodological quality of narrative reviews using international narrative systematic assessment (INSA) tool and a score of at least five is considered good for a narrative review assessed by this scale.<sup>37</sup>

### **Data extraction and synthesis**

We extracted the following information from the final included studies (see tables 1-5): study period, country of study, population type, study setting, sample size, study design, and main outcome measured and discussed the characteristics of included studies under each health effect. The major conclusions that relate to our study objective were synthesized and presented systematically by the results of the interaction of tobacco smoking and HCV infection. We presented HCC, COPD, CVD, DM, CKD and opportunities and benefits of simultaneously treating tobacco smoking and HCV infection.


## **Results**

### **Search results and eligibility assessment**

Figure 1 presents the PRISMA flowchart for the screening and eligibility assessment of identified records. A total of 464 records were identified. Seventy-four duplicate records were excluded, and we screened 390 records for eligibility. One hundred seventy-five records were excluded by reading the title or abstract.

We assessed the full text of the remaining 215 studies for eligibility and excluded 156 studies that did not fulfil inclusion criteria. Among these, 147 studies did not address HCV, tobacco smoking and health outcomes and we could not extract data on the interaction effects, one

study was in children, an appropriate outcome was not assessed in four studies, and four were non-English language studies (Figure 1). Finally, we included 59 eligible studies in the systematic review.



**Figure 1: Results of literature search and screening for studies assessing tobacco smoking, HCV infection and the health effects.**

**Risk of bias and quality assessment in individual studies**

We present the quality assessment scores of included studies in tables 1-5 under specific health outcomes. Of seventeen cross-sectional studies included (four studies on HCC, two studies each on COPD and CVD, six studies on DM, and three studies on CKD), nine had a quality score of 9 and above. The NOS scores of other studies were 8 (five studies), 7 (three studies), and 6 (one study). Among 24 cohort studies, 14 had a NOS score of 9, nine studies had a score of 8 and in one study the score was 6. Five out of eleven case-control studies had a NOS score of 10 and the remaining studies had scores of 9 (four studies) and 8 (three studies). Two systematic reviews had an AMSTAR-2 score of 10 and the methodological quality score for each of the three narrative reviews using the INSA scale was 5.

**Research in context**

*Evidence before this study*

Independent health implications of tobacco smoking and hepatitis C virus infection have been stated. The presence of highly efficacious DAA treatment for HCV infection with growing accessibility globally is well documented.

*Added value of this study*

Interaction of tobacco smoking and HCV infection to cause many disease conditions including HCC, COPD, CVD, DM, and CKD. Tobacco smoking impacts adherence to DAA therapy, rate of SVR in interferon-based treated PLHCV, and occurrence of HCC, CVD, DM, and CKD even with good anti-HCV treatment success. The global expansion of DAA treatment leading to a wider access is an opportunity to initiate smoking cessation treatments simultaneously with HCV treatment.

*Implications of all the available evidence*

Simultaneous initiation of tobacco cessation treatment helps to reduce tobacco smoking burden, tobacco related diseases and maximizes the health gains expected from anti HCV therapy.


**Tobacco smoking and chronic HCV infection-joint health implications**

Tobacco smoking and chronic HCV infection independently increase the risk of many serious health conditions. However, smoking and HCV infection may also act synergistically for some diseases.

**Hepatocellular carcinoma**

Both tobacco smoking (OR = 4.55, 95% confidence interval (CI): 1.90 - 10.91) and chronic HCV infection (OR = 13.36, 95% CI: 4.11 - 43.45) are independently predictive of HCC.<sup>38</sup> A nested case-control study in Europe that showed the

relative importance of tobacco smoking, HCV infection and their unknown interaction effect found 73% of HCC cases were tobacco smokers and nearly one-in-five cases were diagnosed with HCV infection (Figure 2).



**Figure 2:** Relative contribution of smoking and hepatitis C virus infection to hepatocellular carcinoma. The grey area shows the unknown proportion of HCC cases who smoke tobacco and diagnosed HCV. **Adapted from (Trichopoulos, et’al, 2011)**

Although the mechanism is not yet well understood, it is hypothesized that tobacco-related carcinogens metabolized by the liver accelerate carcinogenesis caused by chronic HCV infection. Additionally, smoking can contribute to oxidative stress, a weakened immune system, and insulin resistance which may increase the risk of developing HCC due to HCV infection.<sup>39</sup>

Thirty-two studies (13 cohort, 11 case-control, four cross-sectional, and four reviews) assessed the joint effects of tobacco smoking and HCV infection on HCC. Twenty-two of the 32 included studies were clinical whereas six studies were community-based (Table 1).

**Table 1: Characteristics of studies assessing the interaction between tobacco smoking and HCV infection on HCC**

Study ID	Study period (data collection)	Country	Age range (years)	Population type	Setting	Sample size	Study Design	Main outcome	Quality score
Abdelaziz, 2018	2009-2016	Egypt	57.79 ± 7.56	HCC cases	Clinic	1302	Cohort	Survival of HCC	8
Akiyama, 2011	1995-2004	Japan	40-95	PLHCV	Clinic	556	Cohort	HCC incidence	9
Arase, 2013	1990-2009	Japan	40-64	Diabetes/HCV	Clinic	4302	Cohort	HCC incidence	8
Chiba, 1996	1996	Japan	Adults	PLHCV	Clinic	412	Cohort	HCC incidence	8
Chuang, 2010	1966-2009	World	18+ years	HCV/HBV	Community/clinic	3,807	Review	HCC occurrence	10 <sup>s</sup>
Di Costanzo, 2008	1994-2004	Italy	63 ± 8	Cirrhosis/HCV	Clinic	138	Cohort	HCC incidence	8
Donato, 2006	1990-2005	World	Adults?	HCC	Community/clinic	-	Review	HCC occurrence	10 <sup>s</sup>
El-Zayadi, 2006	2006	World	All ages	PLHCV	Community/clinic	-	Review	Treatment response	5*
Fan, 2015	2011-2012	Taiwan	20+	Adult population	Community	6805	Cross-sectional	Treatment response	8



Franceschi, 2006	1999-2002	Italy	40+	HCC cases /controls	Clinic	660	Case-control	Determinants of HCC	10
Fujita, 2006	1990 - 1999	Japan	40-79	Community	Community	110792	Cohort	Survival	9
Gelatti, 2005	1999-2002	Italy	40-79	HCC cases /controls	Clinic	600	Case-control	Determinants of HCC	9
Goritsas, 1995	1989-1992	Greece	65.8 (mean)	HCC cases /controls	Clinic	170	Case-control	Determinants of HCC	9
Grando-Lemaire, 1999	1990-1992	France	63(28-87)	HCC cases	Clinic	30 HCC cases	Cross-sectional	Interaction of tobacco and HCV	6
Gulnaz, 2013	2012	Pakistan	9+	HCC cases /controls	Clinic	199	Case-control	Determinants of HCC	8
Hassan, 2008	2000-2006	USA	Adults	HCC cases /controls	Clinic	1380	Case-control	Determinants of HCC	9
Ikeda, 2007	1995-2005	Japan	Adults	Chronic hepatitis	Clinic	872	Cohort	HCC incidence	9
Jeng, 2009	2003-2004	Taiwan	32-79	HCC cases /controls	Clinic	400	Case-control	Determinants of HCC	8
Kai, 2018	1984-2012	Japan	67.2 ± 8.6	HCC cases	Clinic	341	Cross-sectional	Treatment outcomes	8
Kolly, 2017	2010-2012	Switzerland	>18	HCC	Clinic	238	Cohort	Survival	9
Lok, 2009	2001-2004	US	50.1 ± 7.1	Cirrhotic	Clinic	1005	Cohort	HCC Incidence	9
Miura, 2008	2003-2006	Japan	52.3 ± 19.6	PLHCV	Clinic	141	Cohort	HCC incidence	8
Mori, 2000	1992-1997	Japan	30+	General population	Community	3059	Cohort	HCC Incidence	9
Saeed, 2012	2008-2010	Yemen	61.2 ± 12.6	HCC cases	Clinic	88	Cross-sectional	Determinants of HCC	9
Sarma, 2012	2006-2010	Japan	68.8 ± 14.5	HCC/PLHCV	Clinic	191	Case-control	Determinants of HCC	8
Sun, 2003	1990-2001	Taiwan	30-64	Population	Community	12008	Cohort	HCC incidence	9
Tzonou, 1991	1991	Greece	Middle Aged	HCC cases /controls	Clinic	617	Case-control	Determinants of HCC	10
Wang, 2003	1991-2000	Taiwan	Adults	General population	Community	11837	Cohort	HCC incidence	9
Yu, 1991	1986-1987	Taiwan	49.5 ± 11.5	HCC cases /controls	Clinic	254	Case-control	Determinants of HCC	10
Yuan, 2004	1984-2002	US	Adults	PLHCV and controls	Community	730	Case-control	Determinants of HCC	10
Yun, 2010	2002-2006	Korea	30+	Cases and controls	Clinic	1035	Case-control	Determinants of HCC	10
Zhao, 2013	2012	China	-	PLHCV smokers	Clinic/community	-	Review	Occurrence of HCC	5*

\* International Narrative Systematic Assessment (INSA) tool for assessing the scientific methodological quality of reviews.

<sup>§</sup> AMSTAR-2 criteria for quality of systematic reviews and meta-analysis

The risk of developing HCC is higher in PLHCV who smoke compared with non-smokers. A longitudinal clinical study of 4302 adult PLHCV aged 40 years and older in Japan found the hazard of developing HCC in PLHCV who smoked  $\geq 20$  cig/day was 1.43 times higher compared with PLHCV who smoked  $< 20$  cig/day.<sup>40</sup> A cohort study of HCV related HCC cases in Taiwan found an additive interaction between HCV infection and tobacco smoking on HCC with (RR = 3.9, 95%CI: 2.0 - 7.7) in PLHCV who smoke compared with HCV negative smokers (RR= 1.1, 95% CI: 0.7 - 1.7) and PLHCV who don't smoke (RR = 2.1, 95%CI: 0.8 - 5.3).<sup>41</sup>

A meta-analysis of six observational studies that calculated the joint effects of tobacco smoking and HCV infection found a multiplicative interaction between the two for HCC risk.

The relative risk of HCC was 15.4 times higher for HCV positive smokers compared with HCV negative smokers (RR = 23.1 versus RR=1.5). The effect was nearly 3 times higher for PLHCV smokers compared with PLHCV non-smokers (RR = 23.1 vs RR = 7.94).<sup>39</sup> In addition, a review of community-based and clinical studies on HCC aetiology in Southern Europe found tobacco smoking as an important co-factor that aggravates the progression of a hepatic lesion and hence the development of HCC in PLHCV.<sup>42</sup>

Tobacco smoking has a negative impact on treatment outcomes of HCV infection. Tobacco smoking in PLHCV has a negative impact on SVR gained from interferon-based therapy and prevention of HCC occurrence.<sup>43,44</sup> However, the role of tobacco smoking on SVR in DAA treated patients is not yet investigated.

Tobacco smoking increases the odds of dying from HCC in PLHCV. In a case-control study of PLHCV and HCV negative persons in Japan, current smokers had 9.6 times higher odds of dying from HCC (OR = 9.6, 95% CI: 1.50 - 61.36) compared with non-smokers while the odds of death from HCC among HCV negative smokers was 1.71 times higher and not statistically significant (OR = 1.71, 95%CI: 0.58 - 5.08). A dose-response relationship exists between death from HCC mortality and the number of cigarettes smoked per day. PLHCV who smoked  $\geq 20$  cig/day had 9.1 times higher odds of dying from HCC (OR = 9.1, 95% CI: 1.10 - 75.05) compared with never-smokers but it was not significant in HCV negative persons who smoked  $\geq 20$  cigarettes (AOR = 1.27, 95%CI: 0.38 - 4.20). This study also found the odds of dying from HCC in PLHCV who smoked cigarettes for 35 or more years was nearly 7 times greater than that in never-smokers (AOR = 6.99, 95%CI: 1.03 - 47.51) while it was 1.27 times higher in PLHCV negative persons who smoked for 35 or more years compared with PLHCV negative never-smokers (OR = 1.27, 95%CI: 0.38 - 4.20).<sup>45</sup>

Similarly, in a cohort study of adult HCC patients with HCV/HBV coinfection, smokers had nearly 3 times higher hazards of dying from HCC compared to non-smokers with HCV/HBV infection (HR = 2.99, 95%CI: 1.7 - 5.23).<sup>46</sup> Both tobacco smoking and HCV infection affect survival after surgery for HCC. In a retrospective cohort study of smoking and surgical outcomes, current smokers with HCV related HCC had 1.69 times higher hazards of dying after hepatic resection compared with non-smokers (HR = 1.69, 95%CI: 1.18 - 2.42).<sup>47</sup>

### **Cardiovascular diseases**

Eight studies assessed the joint effect of tobacco smoking and HCV infection on CVDs. Five studies employed a cohort design<sup>44,48-50</sup> while three studies were cross-sectional.<sup>21,26,51</sup> Six

studies were conducted in a clinical setting and two of the eight included studies were community-based. Four studies<sup>44,48,50,51</sup> had a high NOS quality assessment score of 9, three studies<sup>21,49,52</sup> had a score of 8, and one study<sup>26</sup> had a score of 7 (Table 2).

**Table 2: Characteristics of studies on the interaction between tobacco smoking and HCV infection on CVD risk.**

Study ID	Study period (data collection)	Country	Age (years)	Population type	Setting	Sample size	Study Design	Main outcome	Quality score
Bedimo, 2010	1996-2004	USA	45·8 ±11·3	PLHIV /PLHCV	Clinic	19424	Cohort	Cerebrovascular events	9
Cacoub, 2018	2006-2015	France	>18	PLHCV	Clinic	878	Cohort	Major adverse cardiovascular events	8
Chew, 2015	2001-2009	USA	20-79	PLHCV/controls	Community	237069	Cohort	Coronary heart disease	9
Coppo, 2015	2005 - 2012	Italy	>18	HCV+/-	Clinic	1266	Cohort	Microangiopathy	9
Petta, 2012	2012	Italy	23-75	PLHCV /controls	Clinic	348	Cross-sectional	Carotid plaques	9
Roed, 2014	2010 - 2011	Denmark	51	PLHCV/controls	Community/clinic	120	Cross-sectional	Coronary artery disease	7
Tsao, 2008	2002-2006	Taiwan	34·7 ± 13·2	Transplant	Clinic	112	Cohort	Survival	8
Younossi, 2013	1999-2010	USA		General population	Clinic	19741	Cross-sectional	Metabolic syndrome	8

There is a well-documented relationship between HCV infection and tobacco smoking for risk of CVD development.<sup>44,50</sup> Tobacco smoking in PLHCV contributes to an increased Framingham Risk Score ( $p<0.001$ )<sup>50</sup> and the risk of acquiring major adverse cardiovascular events (HR = 1.86, 95%CI: 1.03 - 3.41).<sup>49,53</sup> HCV infection and tobacco smoking interact positively to result in increased risk of CVD-related mortality (AOR = 1.65, 95%CI: 1.07 – 2.56 ), cerebrocardiovascular events (OR = 1.30, 95% CI: 1.10 – 1.55 ),<sup>52,54</sup> and the rate of tobacco smoking in the HCV positive cohort, with high rate of cardiovascular diseases, was significantly higher (76.23% vs 29.85%).<sup>21</sup>

### Chronic obstructive pulmonary disease

It has been theorized that the increased T lymphocytes seen in PLHCV could influence lung function decline in COPD patients.<sup>55</sup> Furthermore, COPD lung inflammation may be amplified by latent viral infections such as chronic HCV.<sup>56</sup>

Only three studies provided information on the interaction between tobacco smoking, HCV infection, and COPD including asthma (Table 3).

**Table 3: Characteristics of studies on the relationship between tobacco smoking, and HCV infection, and the risk of COPD**

Study ID	Study period (data collection)	Country	Age (years)	Population type	Setting	Sample size	Study Design	Main outcome	Quality score
Fischer, 2014	2014	Brazil	>18	HCV/HIV	Clinic	1068	Cross-sectional	COPD	8
Kanazawa, 2003	1997-2002	Japan	59.5±6.2	COPD	Clinic	59	Cohort	COPD/FEV1	8
Nakashima-2011	2004	Japan	57.8	Asthmatic	Clinic	1327	Cross-sectional	COPD/Asthma	8

A clinical study of PLHCV and HCV negative adult patients with asthma in an outpatient unit identified that PLHCV with asthma were more likely to be smokers compared with the HCV negative comparison group.<sup>57</sup> A longitudinal study of 59 COPD patients (15 HCV-negative ex-smokers; 14 HCV-negative current smokers; 14 HCV-positive ex-smokers; 16 HCV-positive current smokers) found the decline in lung function (FEV1) among HCV positive current smokers was higher than ex-smokers or HCV negative current smokers after five years of follow-up. This suggests chronic HCV infection could accelerate a decline in lung function in COPD patients who smoke.<sup>55</sup> Different from other reports, a clinic-based cross-sectional study of with HCV and/or HIV infection in Brazil found no independent association between HCV and COPD (OR = 0.82, 95% CI: 0.51 – 1.31) and current smoking was not associated with the development of COPD in PLHCV (OR = 1.00, 95% CI: 0.91 – 1.11).<sup>58</sup>

### Diabetes mellitus

Chronic HCV infection is associated with a higher risk of DM as a result of direct viral role or secondary to HCV-induced liver damage, both of which lead to abnormal glucose metabolism.<sup>59</sup> In PLHCV who smoke, HCV-induced hepatitis, high triglyceride levels, and physical inactivity lead to insulin resistance eventually aggravating the chance of occurrence of DM.<sup>60,61</sup>

Table 4 shows the characteristics of studies that assessed the role of tobacco smoking and HCV infection to cause DM. Three of the 11 studies included were community-based cohort or cross-sectional (Table 4).

Table 4: Characteristics of studies on the interaction between tobacco smoking and HCV infection and diabetes mellitus

Study ID	Study period (data collection)	Country	Age range (years)	Population type	Setting	Sample size	Study Design	Main outcome	Quality score
Basseri, 2010	1998-2007	USA	48.5±0.4	PLHCV	Clinic	800	Cross-sectional	DM	10
Caliskan, 2009	2009	Turkey	Not stated	Hemodialysis	Clinic	72	Cohort	DM	8
Coppo, 2015	2005-2006	Italy	>18	Diabetics	Clinic	173	Cohort	DM complications	9
Lai, 2006	1999-2002	Taiwan	30+	Diabetics	Community	5732	Cohort	HCC incidence	8
Mello, 2006	2003-2004	Brazil	18-65	PLHCV	Clinic	30	Cohort	Insulin	6

								resistance	
Nagao, 2008	1988 - 2005	Japan	60 ± 11.5	PLHCV	Clinic	87	Cross-sectional	Insulin resistance	7
Rao, 2015	February -June 2011	China	18+	PLHCV	Clinic	947	Cross-sectional	Glycometabolism	10
Ruhl, 2014	1999-2010	USA	20+	PLHCV	Community	15128	Cross-sectional	DM	10
Wang, 2007	1997-2003	Taiwan	40+	PLHCV/HBV	Community	4958	Cohort	DM	9
Younossi, 2013	1999-2010	USA	18+	Community	Clinic	19741	Cross-sectional	Metabolic syndrome	10
Khalili, 2010	2010	USA	Adults	PLHCV/HCV-	Clinic	74	Cross-sectional	Insulin resistance	9

The odds of developing DM were 1.4 - 5 times higher in PLHCV who smoke compared with PLHCV who do not smoke. According to a clinic-based cross-sectional study of 800 PLHCV in the US, HCV infection confers 1.44 times higher odds of DM (OR = 1.44, 95%CI: 1.16 - 1.78) compared with general population controls. On the other hand, the odds of tobacco smoking were more than 5 times higher in PLHCV (OR = 5.52, 95%CI: 4.77 - 6.4) compared to HCV negative controls.<sup>62</sup> Additionally, tobacco smoking in PLHCV is significantly associated with abnormal glycometabolism, insulin resistance, and development of DM.<sup>63-66</sup> Likewise, current tobacco smoking nearly tripled the hazards of DM-related complications (HR = 2.94, 95% CI: 1.06 - 8.17) compared with never-smokers independent of HCV status, but HCV infection was not independently associated with DM-related complications (HR = 0.74, 95%CI: 0.33 - 1.71).<sup>44</sup>

## Renal diseases

We found five studies that assessed the interaction of tobacco smoking and HCV infection on occurrence and complications of renal diseases (Table 5).

**Table 5: Characteristics of included studies assessing the interaction between tobacco smoking and HCV infection on chronic kidney diseases**

Study ID	Study period (data collection)	Country	Age range (years)	Population type	Setting	Sample size	Study Design	Main outcome	Quality score
Basseri, 2010	1998-2007	USA	48.5±0.4	PLHCV	Clinic	800	Cross-sectional	Co-morbidities	10
Butt, 2006	1997-1998	USA	18-90	PLHCV/HIV	Clinic	5737	Cross-sectional	Co-morbidities	9
Su, 2015	2008-2010	Taiwan	>18	PLHCV	Clinic	10463	Case-control	Co-morbidities	9
Underner, 2008	2008	France	Adults	PLHCV	Clinic	-	Review	CKD	5*
Yucel, 2004	2004	Turkey	25-65	ESRD	Clinic	76	Cross-sectional	Bone mineral density	7

A large cross-sectional study of PLHCV on dialysis found the odds of developing CKD in smokers was 1.59 (95% CI: 1.36 - 1.87) times higher than that in non-smokers.<sup>67</sup> In the same way, tobacco smoking in PLHCV increases the risk of renal cell carcinoma and chronic nephropathies.<sup>68</sup> Tobacco smoking also aggravates the development of bone mineral density defects in PLHCV on haemodialysis.<sup>69</sup>

## Discussion

Tobacco smoking and chronic HCV infection each account for a significant disease burden and mortality worldwide. These two conditions also interact to result in several diseases, including HCC, COPD, CVD, DM, and CKD. Tobacco smoking and HCV infection share a few risk factors that partly explain their co-occurrence and offer the potential to address both health issues simultaneously.

The higher rate of smoking in PLHCV compared with the general population is unsurprising due to their shared underlying risk factors.<sup>20,22</sup> Even with successful SVR after treatment, tobacco smoking, and HCV infection both contribute to the development of many chronic diseases.<sup>49,70</sup> This emphasizes that optimal health outcomes expected from DAAs may not be achieved without simultaneously addressing tobacco smoking as many PLHCV will still be at risk of developing many of these health conditions due to their smoking even if they are cured of HCV. Combining smoking cessation assistance with HCV treatment may be a way to optimize health outcomes for this population.

Increased access to highly effective DAAs for the treatment of HCV is revolutionizing the prospect of ending the HCV epidemic. The new DAA therapies have many benefits including improved efficacy to over 90% for all genotypes<sup>9</sup> compared with only 45 - 75% efficacy for genotypes 1, 2, and 3 with their predecessors.<sup>71</sup> Several HICs such as Australia, Canada, and the US publicly subsidized HCV treatment to increase coverage of anti-HCV treatment.<sup>9,72,73</sup> As a result, treatment uptake for HCV significantly increased.<sup>74</sup> Globally, the number of people who initiated DAA-based treatment for HCV rose between 2015 and 2016, from approximately 1 million to 1.5 million and there is a strategy to increase coverage from 7% in 2015 to 80% by 2030.<sup>75</sup> However, the success rate of HCV therapy can be undermined by substance use during the treatment period by creating poor treatment adherence and thus relapse of HCV.<sup>76</sup> Tobacco smoking reduces the rate of SVR in PLHCV treated with interferon-based antivirals but the impact of smoking on SVR in DAAs treated PLHCV is an area of further investigation.

Given that smoking prevalence is high among PLHCV, the importance of reducing smoking in this population should receive greater attention. Therefore, the global initiative to scale-up access to DAAs and the current move to roll-out HCV treatment creates an opportunity for treatment of tobacco addiction among a population with high smoking prevalence.<sup>77,78</sup> Approaches to address both will have multiple benefits to both patients and the health system

and increases the likelihood that DAAs reduce morbidity and mortality rates better than delivering DAAs alone.<sup>79</sup>

Tobacco smokers may face many challenges due to lack of access to care, poor adherence to therapy, and HCV reinfection due to risks such as injecting drug use. However, smokers living with HCV can be assisted to quit smoking with both pharmacotherapy and behavioural interventions where close monitoring of adherence and compliance to treatment is promoted.<sup>80</sup> This could boost achievement of maximum health benefits from the treatments of both tobacco addiction and HCV infection.<sup>80,81</sup>

Currently, the greatest potential for integrating smoking cessation into HCV treatment is in HICs where both HCV and smoking cessation treatment are often publicly subsidized. However, LMICs present a greater challenge, where rates of diagnosis and treatment of HCV and smoking addiction remain low. As a result, access to effective smoking cessation assistance is limited in many LMICs although WHO includes nicotine replacement therapy on its list of essential medicines. Therefore, country-specific strategy to increase access to both HCV and smoking cessation treatments is vital in LMICs. Furthermore, the lessons from increasing access to HIV treatment could be helpful to improve access to HCV and tobacco addiction. Some options include price subsidy for PLHCV, strengthening the health system, advocacy,<sup>82</sup> and integrating the smoking cessation services into HCV care settings to provide a one-stop-shop service.

## **Conclusions**

Tobacco smoking and HCV infection are important global public health concerns each posing numerous health challenges. They also interact in an additive or multiplicative way to result in many serious diseases.

The co-occurrence of tobacco smoking in PLHCV has diverse long-term negative health consequences. This shortens the time to occurrence of health complications such as HCC and increases the risk of occurrence of DM, CVD, CKD, and COPD.

Failing to address tobacco addiction in PLHCV will undermine the potential health gains that could be achieved from highly efficacious DAAs. It is recommended that HCV treatment is used as an entry to provide smoking cessation interventions concurrently. The scale-up of DAAs globally now presents a unique opportunity to address tobacco smoking addiction. Integrated treatment of tobacco smoking at HCV treatment settings can be realized by price subsidy, strengthening the health system, and advocacy.



We recommend studies that evaluate the feasibility and cost-effectiveness of integrating smoking cessation care into HCV treatment settings, particularly in LMICs. Population-based studies evaluating the confounding effect of alcohol on the interaction between tobacco smoking and HCV infection are required. We also recommend longitudinal studies to investigate the effect of tobacco smoking on SVR in PLHCV treated with DAAs.

### **Declaration of interest**

None declared.

### **Acknowledgements**

We thank the Herston Health Sciences Library for technical support during literature searching.

### **References**

1. Sergio M. B, Hedskog C, Bandita Parhy, et al. Identification of a Novel Hepatitis C Virus Genotype From Punjab, India: Expanding Classification of Hepatitis C Virus Into 8 Genotypes. *The Journal of Infectious Diseases* 2018; **218** 1722–9.
2. Douglas MW, Tay S, Eden J-S, George J. Hepatitis C Virus Genotype 8 Infection—Successful Treatment With Sofosbuvir/Velpatasvir. *The Journal of Infectious Diseases* 2019.
3. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. *J Hepatol* 2014; **61**(1 Suppl): S45-57.
4. Arnolfo, Petruzzello, Samantha, et al. Global epidemiology of hepatitis C virus infection: an update of the distribution and circulation of hepatitis C virus genotypes. *World J Gastroenterol* 2016; (34): 7824-40.
5. Thrift AP, El-Serag HB, Kanwal F. Global epidemiology and burden of HCV infection and HCV-related disease. *Nat Rev Gastroenterol Hepatol* 2017; **14**(2): 122-32.
6. Peacock A, Leung J, Larney S, et al. Global statistics on alcohol, tobacco, and illicit drug use: 2017 status report. *Addiction (Abingdon, England)* 2018; **113**(10): 1905-26.
7. Mahmud S, Kouyoumjian SP, Al Kanaani Z, Chemaitelly H, Abu-Raddad LJ. Individual-level key associations and modes of exposure for hepatitis C virus infection in the Middle East and North Africa: a systematic synthesis. *Ann Epidemiol* 2018; **28**(7): 452-61.
8. Mohlman MK, Saleh DA, Ezzat S, et al. Viral transmission risk factors in an Egyptian population with high hepatitis C prevalence. *BMC Public Health* 2015; **15**: 1030.
9. Thompson AJ. Australian recommendations for the management of hepatitis C virus infection: a consensus statement. *Med J Aust* 2016; **204**(7): 268-72.
10. Larouche A, Gaetan G, El-Bilali N, et al. Seronegative hepatitis C virus infection in a child infected via mother-to-child transmission. *J Clin Microbiol* 2012; **50**(7): 2515-9.



11. Tohme RA, Holmberg SD. Transmission of hepatitis C virus infection through tattooing and piercing: a critical review. *Clin Infect Dis* 2012; **54**(8): 1167-78.
12. World Health Organization (WHO). WHO report on the global tobacco epidemic 2017: Monitoring tobacco use and prevention policies. 2017.
13. Gowing LR, Ali RL, Allsop S, et al. Global statistics on addictive behaviours: 2014 status report. *Addiction (Abingdon, England)* 2015; **110**(6): 904-19.
14. Australia Institute of Health and Welfare (AIHW). National Drug Strategy Household Survey (NDHS) 2016 - key findings Canberra: AIHW, 2017.
15. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. *Circulation* 2016; **133**(4): e38-360.
16. Office of National Statistics(GB). Adult smoking habits in the UK. 2017. Available at:<https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/drugusealcoholandsmoking/datasets/adultsmokinghabitsingreatbritain> (accessed July 13 2018).
17. Dickerson F, Schroeder J, Katsafanas E, et al. Cigarette smoking by patients with serious mental illness, 1999–2016: an increasing disparity. *Psychiatric Services* 2017; **69**(2): 147-53.
18. Weinberger AH, Gbedemah M, Wall MM, Hasin DS, Zvolensky MJ, Goodwin RD. Cigarette use is increasing among people with illicit substance use disorders in the United States, 2002–14: emerging disparities in vulnerable populations. *Addiction (Abingdon, England)* 2018; **113**(4): 719-28.
19. Akhtar-Khaleel WZ, Cook RL, Shoptaw S, et al. Trends and Predictors of Cigarette Smoking Among HIV Seropositive and Seronegative Men: The Multicenter Aids Cohort Study. *Aids Behav* 2016; **20**(3): 622-32.
20. Gidding HF, Law MG, Amin J, et al. Hepatitis C treatment outcomes in Australian clinics. *Med J Aust* 2012; **196**(10): 633-7.
21. Younossi ZM, Stepanova M, Nader F, Younossi Z, Elsheikh E. Associations of chronic hepatitis C with metabolic and cardiac outcomes. *Aliment Pharmacol Ther* 2013; **37**(6): 647-52.
22. Shuter J, Litwin AH, Sulkowski MS, et al. Cigarette Smoking Behaviors and Beliefs in Persons Living With Hepatitis C. *Nicotine Tob Res* 2017; **19**(7): 836-44.
23. Kim RS, Weinberger AH, Chander G, Sulkowski MS, Norton B, Shuter J. Cigarette Smoking in Persons Living with Hepatitis C: The National Health and Nutrition Examination Survey (NHANES), 1999-2014. *Am J Med* 2018; **131**(6): 669-75.
24. West R. Tobacco smoking: Health impact, prevalence, correlates and interventions. *Psychol Health* 2017; **32**(8): 1018-36.
25. Action on Smoking and Health. Smoking statistics. 2017. Available at: <http://ash.org.uk/category/information-and-resources/fact-sheets> (accessed July 13 2018).
26. Roed T, Kristoffersen US, Knudsen A, et al. Increased prevalence of coronary artery disease risk markers in patients with chronic hepatitis C--a cross-sectional study. *Vasc Health Risk Manag* 2014; **10**: 55-62.

27. Wang CS, Wang ST, Yao WJ, Chang TT, Chou P. Hepatitis C virus infection and the development of type 2 diabetes in a community-based longitudinal study. *American journal of epidemiology* 2007; **166**(2): 196-203.
28. Sarma MP, Asim M, Medhi S, Bharathi T, Kar P. Hepatitis C virus-related hepatocellular carcinoma: a case-control study from India. *J Med Virol* 2012; **84**(7): 1009-17.
29. Silva DR, Stiff J, Cheinquer H, Knorst MM. Prevalence of hepatitis C virus infection in patients with COPD. *Epidemiol Infect* 2010; **138**(2): 167-73.
30. Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB, Sulkowski MS. Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review. *Ann Intern Med* 2017; **166**(9): 637-48.
31. Ponziani FR, Miele L, Tortora A, et al. Treatment of early-stage chronic hepatitis C virus infection. *Expert Rev Clin Pharmacol* 2018; **11**(5): 519-24.
32. Rowe IA. Lessons from Epidemiology: The Burden of Liver Disease. *Dig Dis* 2017; **35**(4): 304-9.
33. Ayoub HH, Abu-Raddad LJ. Impact of treatment on hepatitis C virus transmission and incidence in Egypt: A case for treatment as prevention. *J Viral Hepat* 2017; **24**(6): 486-95.
34. Wells G. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analysis 2004. [http://www.ohri.ca/programs/clinical\\_epidemiology.oxford.htm](http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm) (accessed June 12, 2018).
35. Modesti PA, Reboldi G, Cappuccio FP, et al. Panethnic Differences in Blood Pressure in Europe: A Systematic Review and Meta-Analysis. *PLoS One* 2016; **11**(1): e0147601.
36. Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. *BMJ* 2017; **358**: j4008.
37. La Torre G, Backhaus I, Mannocci AJS, Sciences. Rating for narrative reviews: concept and development of the International Narrative Systematic Assessment tool. 2015; **2**(2).
38. Trichopoulos D, Bamia C, Laggiou P, et al. Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case-control study. *Journal of the National Cancer Institute* 2011; **103**(22): 1686-95.
39. Chuang SC, Lee YC, Hashibe M, Dai M, Zheng T, Boffetta P. Interaction between cigarette smoking and hepatitis B and C virus infection on the risk of liver cancer: a meta-analysis. *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology* 2010; **19**(5): 1261-8.
40. Arase Y, Kobayashi M, Suzuki F, et al. Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C. *Hepatology* 2013; **57**(3): 964-73.
41. Sun CA, Wu DM, Lin CC, et al. Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan. *American journal of epidemiology* 2003; **157**(8): 674-82.

42. Donato F, Gelatti U, Limina RM, Fattovich G. Southern Europe as an example of interaction between various environmental factors: a systematic review of the epidemiologic evidence. *Oncogene* 2006; **25**(27): 3756-70.
43. El-Zayadi AR. Heavy smoking and liver. *World J Gastroenterol* 2006; **12**(38): 6098-101.
44. Coppo C, Bonfanti D, Bo S, et al. Risk of microangiopathy in type 2 diabetes mellitus patients with or without chronic hepatitis C: Results of a retrospective long-term controlled cohort study. *Dig Liver Dis* 2015; **47**(5): 405-10.
45. Fujita Y, Shibata A, Ogimoto I, et al. The effect of interaction between hepatitis C virus and cigarette smoking on the risk of hepatocellular carcinoma. *British journal of cancer* 2006; **94**(5): 737-9.
46. Kolly P, Knopfli M, Dufour JF. Effect of smoking on survival of patients with hepatocellular carcinoma. *Liver international : official journal of the International Association for the Study of the Liver* 2017; **37**(11): 1682-7.
47. Kai K, Komukai S, Koga H, et al. Correlation between smoking habit and surgical outcomes on viral-associated hepatocellular carcinomas. *World J Gastroenterol* 2018; **24**(1): 58-68.
48. Bedimo R, Westfall AO, Mugavero M, Drechsler H, Khanna N, Saag M. Hepatitis C virus coinfection and the risk of cardiovascular disease among HIV-infected patients. *HIV medicine* 2010; **11**(7): 462-8.
49. Cacoub P, Nahon P, Layese R, et al. Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients. *Am Heart J* 2018; **198**: 4-17.
50. Chew KW, Bhattacharya D, McGinnis KA, et al. Short Communication: Coronary Heart Disease Risk by Framingham Risk Score in Hepatitis C and HIV/Hepatitis C-Coinfected Persons. *AIDS Res Hum Retroviruses* 2015; **31**(7): 718-22.
51. Petta S, Torres D, Fazio G, et al. Carotid atherosclerosis and chronic hepatitis C: a prospective study of risk associations. *Hepatology* 2012; **55**(5): 1317-23.
52. Tsao CI, Chen RJ, Chou NK, et al. The influence of donor characteristics on survival after heart transplantation. *Transplantation proceedings* 2008; **40**(8): 2636-7.
53. Kanellopoulou T, Alexopoulou A, Kontopidou FN, Konstantinides P, Papatheodoridis GV. The significance of platelet microparticles in patients with chronic hepatitis C and their association with antiviral treatment and smoking. *Ann Gastroenterol* 2016; **29**(2): 201-7.
54. Petta S, Maida M, Macaluso FS, et al. Hepatitis C Virus Infection Is Associated With Increased Cardiovascular Mortality: A Meta-Analysis of Observational Studies. *Gastroenterology* 2016; **150**(1): 145-+.
55. Kanazawa H, Hirata K, Yoshikawa J. Accelerated decline of lung function in COPD patients with chronic hepatitis C virus infection: a preliminary study based on small numbers of patients. *Chest* 2003; **123**(2): 596-9.
56. Retamales I, Elliott WM, Meshi B, et al. Amplification of inflammation in emphysema and its association with latent adenoviral infection. *Am J Respir Crit Care Med* 2001; **164**(3): 469-73.

57. Nakashima T, Yokoyama A, Ohnishi H, et al. Chronic hepatitis C virus infection is associated with more severe asthma. *Allergology international : official journal of the Japanese Society of Allergology* 2011; **60**(3): 299-304.
58. Fischer WA, 2nd, Drummond MB, Merlo CA, et al. Hepatitis C virus infection is not an independent risk factor for obstructive lung disease. *Copd* 2014; **11**(1): 10-6.
59. White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. *J Hepatol* 2008; **49**(5): 831-44.
60. Reynolds K, Liese AD, Anderson AM, et al. Prevalence of tobacco use and association between cardiometabolic risk factors and cigarette smoking in youth with type 1 or type 2 diabetes mellitus. *J Pediatr* 2011; **158**(4): 594-601 e1.
61. Imazeki F, Yokosuka O, Fukai K, Kanda T, Kojima H, Saisho H. Prevalence of diabetes mellitus and insulin resistance in patients with chronic hepatitis C: comparison with hepatitis B virus-infected and hepatitis C virus-cleared patients. *Liver international : official journal of the International Association for the Study of the Liver* 2008; **28**(3): 355-62.
62. Basseri B, Yamini D, Chee G, Enayati PD, Tran T, Poordad F. Comorbidities associated with the increasing burden of hepatitis C infection. *Liver international : official journal of the International Association for the Study of the Liver* 2010; **30**(7): 1012-8.
63. Nagao Y, Kawasaki K, Sata M. Insulin resistance and lichen planus in patients with HCV-infectious liver diseases. *Journal of gastroenterology and hepatology* 2008; **23**(4): 580-5.
64. Rao H, Wei L, Li H, et al. Prevalence of abnormal glycometabolism in treatment-naive patients with hepatitis C virus infection in a Chinese Han population. *Journal of gastroenterology and hepatology* 2015; **30**(6): 1049-56.
65. Mello V, Cruz T, Nunez G, et al. Peripheral insulin resistance during treatment of chronic hepatitis C with pegylated interferon plus ribavirin. *J Med Virol* 2006; **78**(11): 1406-10.
66. Lai MS, Hsieh MS, Chiu YH, Chen TH. Type 2 diabetes and hepatocellular carcinoma: A cohort study in high prevalence area of hepatitis virus infection. *Hepatology* 2006; **43**(6): 1295-302.
67. Butt AA, Evans R, Skanderson M, Shakil AO. Comorbid medical and psychiatric conditions and substance abuse in HCV infected persons on dialysis. *J Hepatol* 2006; **44**(5): 864-8.
68. Underner M, Hadjadj S, Beauchant M, Bridoux F, Debiais F, Meurice JC. [Effects of smoking on the thyroid gland, digestive system, kidney and bone]. *Revue des maladies respiratoires* 2008; **25**(10): 1261-78.
69. Yucel AE, Kart-Koseoglu H, Isiklar I, Kuruinci E, Ozdemir FN, Arslan H. Bone mineral density in patients on maintenance hemodialysis and effect of chronic hepatitis C virus infection. *Renal failure* 2004; **26**(2): 159-64.
70. Hassan MM, Spitz MR, Thomas MB, et al. Effect of different types of smoking and synergism with hepatitis C virus on risk of hepatocellular carcinoma in American men and women: case-control study. *International journal of cancer* 2008; **123**(8): 1883-91.
71. Gane E. Future hepatitis C virus treatment: interferon-sparing combinations. *Liver international : official journal of the International Association for the Study of the Liver* 2011; **31** Suppl 1(s1): 62-7.

72. Rosenthal ES, Graham CS. Price and affordability of direct-acting antiviral regimens for hepatitis C virus in the United States. *Infect Agent Cancer* 2016; **11**(1): 24.
73. Marshall AD, Saeed S, Barrett L, et al. Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study. *CMAJ Open* 2016; **4**(4): E605-E14.
74. Memedovic S, Iversen J, Geddes L, Maher L. Australian Needle Syringe Program Survey National Data Report 2011-2015: Prevalence of HIV, HCV and injecting and sexual behaviour among NSP attendees. *Kirby Institute, UNSW Australia: Sydney* 2016.
75. World Health Organization (WHO). Progress report on access to hepatitis C treatment: focus on overcoming barriers in low- and middle-income countries. Geneva, Switzerland: World Health Organization; 2018.
76. Russell M, Pauly MP, Moore CD, et al. The impact of lifetime drug use on hepatitis C treatment outcomes in insured members of an integrated health care plan. *Drug Alcohol Depen* 2014; **134**: 222-7.
77. Gartner C, Miller A, Bonevski B. Extending survival for people with hepatitis C using tobacco dependence treatment. *Lancet* 2017; **390**(10107): 2033-.
78. World Health Organization (WHO). Global Hepatitis Report, 2017. Geneva: World Health Organization; 2017.
79. Zimmermann T, Hueppe D, Mauss S, et al. Effects of Smoking on Pegylated Interferon alpha 2a and First Generation Protease Inhibitor-based Antiviral Therapy in Naive Patients Infected with Hepatitis C Virus Genotype 1. *J Gastrointestin Liver Dis* 2016; **25**(1): 15-24.
80. Taylor LE, Gholam PM, Schwartzapfel B, Rich JD. Hepatitis C treatment in an HIV-HCV-coinfected patient with drug addiction and psychiatric illness: a case report. *AIDS Read* 2005; **15**(11): 629-31, 34-6, 38.
81. Grebely J, deVlaming S, Duncan F, Viljoen M, Conway B. Current approaches to HCV infection in current and former injection drug users. *J Addict Dis* 2008; **27**(2): 25-35.
82. Assefa Y, Hill PS, Williams OD. Access to hepatitis C virus treatment: Lessons from implementation of strategies for increasing access to antiretroviral treatment. *Int J Infect Dis* 2018; **70**: 65-8.